CN110753751A - 具有增强的免疫抑制的间充质谱系前体或干细胞 - Google Patents

具有增强的免疫抑制的间充质谱系前体或干细胞 Download PDF

Info

Publication number
CN110753751A
CN110753751A CN201880036997.2A CN201880036997A CN110753751A CN 110753751 A CN110753751 A CN 110753751A CN 201880036997 A CN201880036997 A CN 201880036997A CN 110753751 A CN110753751 A CN 110753751A
Authority
CN
China
Prior art keywords
cells
cell
mesenchymal lineage
subject
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880036997.2A
Other languages
English (en)
Chinese (zh)
Inventor
S·伊特斯库
P·西蒙斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mesoblast International SARL
Original Assignee
Mesoblast International SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017901633A external-priority patent/AU2017901633A0/en
Application filed by Mesoblast International SARL filed Critical Mesoblast International SARL
Publication of CN110753751A publication Critical patent/CN110753751A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157—Monocytes, macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201880036997.2A 2017-05-04 2018-05-04 具有增强的免疫抑制的间充质谱系前体或干细胞 Pending CN110753751A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2017901633 2017-05-04
AU2017901633A AU2017901633A0 (en) 2017-05-04 Potency assay for immunosuppression
AU2017901636A AU2017901636A0 (en) 2017-05-04 Method for treating Graft versus Host Disease (GVHD)
AU2017901636 2017-05-04
AU2018900551A AU2018900551A0 (en) 2018-02-21 Potency assay for immunosuppression II
AU2018900551 2018-02-21
PCT/EP2018/061503 WO2018202853A1 (en) 2017-05-04 2018-05-04 Mesenchymal lineage precursor or stem cells with enhanced immunosuppression

Publications (1)

Publication Number Publication Date
CN110753751A true CN110753751A (zh) 2020-02-04

Family

ID=62222586

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880036997.2A Pending CN110753751A (zh) 2017-05-04 2018-05-04 具有增强的免疫抑制的间充质谱系前体或干细胞

Country Status (10)

Country Link
US (1) US20200325450A1 (https=)
EP (2) EP4137562A1 (https=)
JP (3) JP7398959B2 (https=)
KR (2) KR102660506B1 (https=)
CN (1) CN110753751A (https=)
AU (2) AU2018262788B2 (https=)
BR (1) BR112019022901A2 (https=)
CA (1) CA3062112A1 (https=)
SG (1) SG11201909856XA (https=)
WO (1) WO2018202853A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112444479A (zh) * 2021-02-01 2021-03-05 宁波大学 基于并行处理技术的单细胞质谱分析系统及方法
CN115361960A (zh) * 2020-02-19 2022-11-18 迈索布拉斯特国际有限公司 用于治疗慢性移植物抗宿主病的方法
CN118147232A (zh) * 2024-05-09 2024-06-07 中国人民解放军联勤保障部队第九二〇医院 一种过表达tps1间充质干细胞的构建方法及其应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
SI2785359T1 (sl) 2011-11-30 2018-11-30 Astellas Institute For Regenerative Medicine Mezenhimske stromalne celice in uporabe povezane z njimi
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
HK1208054A1 (en) 2012-07-12 2016-02-19 爱姆斯坦生物技术公司 Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
SG11201909856XA (en) * 2017-05-04 2019-11-28 Mesoblast Int Sarl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
JP7793284B2 (ja) * 2020-03-02 2026-01-05 株式会社ガイアバイオメディシン 高活性ｎｋ細胞の処理方法
JP2023530098A (ja) * 2020-06-11 2023-07-13 メゾブラスト・インターナショナル・エスアーエールエル 間葉系前駆細胞又は幹細胞の３ｄ培養
AU2021323475A1 (en) * 2020-08-10 2023-04-13 Mesoblast International Sarl A composition comprising mesenchymal precursor or stem cells and their use
CN113881707B (zh) * 2021-10-25 2023-07-14 中国人民解放军军事科学院军事医学研究院 调控脐带间充质干细胞免疫抑制作用的产品、方法及用途
US20250032552A1 (en) * 2021-12-23 2025-01-30 Mesoblast International Sárl Method of treating severe graft versus host disease
CA3260880A1 (en) * 2022-07-05 2024-01-11 Mesoblast International Sarl CRYOPROVERTED INTERMEDIATE AND BIOLOGICAL ACTIVITY TEST FOR IT
KR20250049337A (ko) 2022-08-09 2025-04-11 엑손모빌 케미칼 패턴츠 인코포레이티드 디페닐실란 가교 c1 대칭 촉매의 제조 방법 및 이로부터 제조된 중합체
WO2024168161A1 (en) * 2023-02-08 2024-08-15 Mesoblast International Sarl Potency assay and manufacturing method
WO2025196663A1 (en) * 2024-03-19 2025-09-25 Mesoblast International Sarl Potency assay and manufacturing method ii

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012000064A1 (en) * 2010-07-02 2012-01-05 Angioblast Systems, Inc. Method of treating graft versus host disease
US20140112893A1 (en) * 2010-10-08 2014-04-24 Mesoblast International Sarl Enhanced msc preparations
US20140248244A1 (en) * 2006-01-13 2014-09-04 Mesoblast International Sarl Mesenchymal Stem Cells Expressing TNF-alpha Receptors
KR20150016117A (ko) * 2013-07-30 2015-02-11 코아스템(주) 인간 골수 유래 중간엽 줄기세포를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약제학적 조성물
WO2015155187A1 (en) * 2014-04-07 2015-10-15 Mesoblast International Sarl Improved stem cell composition
WO2016102597A1 (en) * 2014-12-23 2016-06-30 Mesoblast International Sàrl Method for treating heart failure

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593089A (en) 1980-07-30 1986-06-03 Abbott Laboratories Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides
US4751190A (en) 1985-07-22 1988-06-14 Abbott Laboratories Fluorescence polarization immunoassay and reagents for use therein
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
DE4211351A1 (de) 1992-04-04 1993-10-07 Behringwerke Ag Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung
WO1994026877A1 (en) 1993-05-17 1994-11-24 The Regents Of The University Of California Ribozyme gene therapy for hiv infection and aids
US6541213B1 (en) 1996-03-29 2003-04-01 University Of Washington Microscale diffusion immunoassay
CA2244326C (en) 1997-08-11 2006-03-28 Shinichi Eda Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor
US6566051B1 (en) 1999-01-15 2003-05-20 Medtox Scientific, Inc. Lateral flow test strip
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US7205159B2 (en) 2001-08-20 2007-04-17 Proteome Systems Intellectual Property Pty Ltd. Diagnostic testing process and apparatus
WO2004046729A2 (en) 2002-11-21 2004-06-03 The University Of Leicester Bodily fluid markers of tissue hypoxia
CN101248171B (zh) 2005-04-12 2015-11-25 迈索布拉斯特股份有限公司 通过组织非特异性碱性磷酸酶分离成人多潜能细胞
SG11201909856XA (en) 2017-05-04 2019-11-28 Mesoblast Int Sarl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140248244A1 (en) * 2006-01-13 2014-09-04 Mesoblast International Sarl Mesenchymal Stem Cells Expressing TNF-alpha Receptors
WO2012000064A1 (en) * 2010-07-02 2012-01-05 Angioblast Systems, Inc. Method of treating graft versus host disease
US20140112893A1 (en) * 2010-10-08 2014-04-24 Mesoblast International Sarl Enhanced msc preparations
KR20150016117A (ko) * 2013-07-30 2015-02-11 코아스템(주) 인간 골수 유래 중간엽 줄기세포를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약제학적 조성물
WO2015155187A1 (en) * 2014-04-07 2015-10-15 Mesoblast International Sarl Improved stem cell composition
WO2016102597A1 (en) * 2014-12-23 2016-06-30 Mesoblast International Sàrl Method for treating heart failure

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AMELIA BARTHOLOMEW ET AL.: "Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo" *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115361960A (zh) * 2020-02-19 2022-11-18 迈索布拉斯特国际有限公司 用于治疗慢性移植物抗宿主病的方法
CN112444479A (zh) * 2021-02-01 2021-03-05 宁波大学 基于并行处理技术的单细胞质谱分析系统及方法
CN112444479B (zh) * 2021-02-01 2021-05-07 宁波大学 基于并行处理技术的单细胞质谱分析系统及方法
CN118147232A (zh) * 2024-05-09 2024-06-07 中国人民解放军联勤保障部队第九二〇医院 一种过表达tps1间充质干细胞的构建方法及其应用

Also Published As

Publication number Publication date
JP2020518260A (ja) 2020-06-25
WO2018202853A1 (en) 2018-11-08
EP4137562A1 (en) 2023-02-22
KR102884611B1 (ko) 2025-11-12
SG11201909856XA (en) 2019-11-28
KR102660506B1 (ko) 2024-04-25
EP3619294A1 (en) 2020-03-11
US20200325450A1 (en) 2020-10-15
AU2018262788B2 (en) 2024-08-15
KR20200003044A (ko) 2020-01-08
JP2026034487A (ja) 2026-02-27
JP7787130B2 (ja) 2025-12-16
JP2023174760A (ja) 2023-12-08
JP7398959B2 (ja) 2023-12-15
BR112019022901A2 (pt) 2020-05-19
CA3062112A1 (en) 2018-11-08
AU2024227344A1 (en) 2024-10-31
KR20240056790A (ko) 2024-04-30
AU2018262788A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
JP7787130B2 (ja) 向上した免疫抑制作用を有する間葉系前駆または幹細胞
JP2022512913A (ja) 遺伝子操作されたｔ細胞を作製するための方法
JP6315989B2 (ja) Ｔ細胞性免疫不全の治療法
WO2018229163A1 (en) Methods of activating v delta 2 negative gamma delta t cells
KR20180033537A (ko) Pd-l1 발현 조혈 줄기 세포 및 용도
KR101786862B1 (ko) 류마티즘성 질환을 치료 또는 예방하는 방법
JP4730733B2 (ja) ４型葉酸受容体の発現を指標とした制御性ｔ細胞の検出方法、及び免疫賦活剤
KR102009056B1 (ko) 조골세포 기능의 향상방법
JP2007521803A (ja) レギュレーター／サプレッサーｔリンパ球の同定および調製のための方法、その組成物、並びにその使用
US10591465B2 (en) Methods and kits for labeling, detection and isolation of Foxp3+ regulatory T cells, isolated population of Foxp3+ regulatory T cells thus obtained and uses thereof
JP2025521740A (ja) 凍結保存中間体及びそれに対する効力アッセイ
JP2026507152A (ja) 全身性自己免疫疾患を処置するための細胞療法
HK40088319A (en) Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
WO2025082502A1 (en) Pan t cells and methods of manufacturing of the same
JP2026504544A (ja) 効力アッセイ、及び製造方法
Willemze et al. Physicians Abstracts EBMT 2008

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination